IRIS
MOSCARELLA, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 827
NA - Nord America 824
AS - Asia 234
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.892
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 822
IE - Irlanda 413
CN - Cina 124
GB - Regno Unito 108
DE - Germania 89
IT - Italia 81
SG - Singapore 78
GR - Grecia 47
SE - Svezia 27
UA - Ucraina 23
FI - Finlandia 14
TR - Turchia 12
BE - Belgio 11
FR - Francia 8
IN - India 8
KR - Corea 5
BR - Brasile 4
ES - Italia 3
NL - Olanda 3
AR - Argentina 2
ID - Indonesia 2
IQ - Iraq 2
MX - Messico 2
EU - Europa 1
IL - Israele 1
IR - Iran 1
SA - Arabia Saudita 1
Totale 1.892
Salva come PNG Salva come JPEG
Città #
Dublin 408
Chandler 216
New York 136
Bremen 61
Princeton 59
Roxbury 57
Singapore 52
Medford 43
Jacksonville 42
Boardman 30
Des Moines 25
Beijing 20
Cambridge 16
Wilmington 15
Nanjing 13
Jinan 12
Brussels 11
Naples 11
Caserta 10
Ann Arbor 9
Sivas 8
Helsinki 7
Hyderabad 7
Shenyang 7
Hebei 6
Hangzhou 5
Houston 5
Lappeenranta 5
Seoul 5
Woodbridge 5
Zhengzhou 5
Tianjin 4
Ashburn 3
Casier 3
Changsha 3
Düsseldorf 3
Guangzhou 3
Haikou 3
Lanzhou 3
Marano Di Napoli 3
Munich 3
Ningbo 3
Taiyuan 3
Catamarca 2
Caçador 2
Jiaxing 2
Malang 2
Milan 2
Monterrey 2
Norwalk 2
Nuremberg 2
Oristano 2
Padova 2
Palermo 2
Paris 2
Piombino 2
Puxian 2
San Giovanni In Fiore 2
San Mateo 2
Santa Maria Capua Vetere 2
São Paulo 2
Taizhou 2
West Jordan 2
Aigaleo 1
Amsterdam 1
Andover 1
Ascoli Piceno 1
Athens 1
Bari 1
Boston 1
Dalmine 1
Duncan 1
Edinburgh 1
Este 1
Fairfield 1
Gallipoli 1
Grafing 1
Groningen 1
Hamm 1
Irakleio 1
Jerusalem 1
Kunming 1
Livorno 1
Nanchang 1
Napoli 1
Pensacola 1
Pievepelago 1
Redmond 1
Riyadh 1
Rome 1
Sennori 1
Stockholm 1
Tehran 1
Valladolid 1
Xiangfen 1
Yicheng 1
Totale 1.421
Salva come PNG Salva come JPEG
Nome #
Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: Results from a multicenter Italian experience. 65
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 57
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 56
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 53
Clinical findings after bioresorbable vascular scaffold implantation in an unrestricted cohort of patients with ST-segment elevation myocardial infarction (from the RAI registry) 51
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 51
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 47
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. 46
Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A contemporary reappraisal 45
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 45
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 44
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 43
Combined Effect of Mediterranean Diet and Aerobic Exercise on Weight Loss and Clinical Status in Obese Symptomatic Patients with Hypertrophic Cardiomyopathy 43
Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study) 42
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 42
Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry) 41
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 41
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 41
Bioresorbable Vascular Scaffolds in In-Stent Restenosis 37
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 36
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 36
Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? 35
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 35
Bioabsorbable drug-eluting vascular scaffold for the treatment of coronary in-stent restenosis: A two center registry 34
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management 33
Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry 32
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 32
One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry 30
Molecular Basis of Inflammation in the Pathogenesis of Cardiomyopathies 29
Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study 29
One-Year Clinical Outcomes After Unrestricted Implantation of Absorb Bioresorbable Scaffold (RAI Registry) 28
Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial 28
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 28
Annular size and interaction with trans-catheter aortic valves for treatment of severe bicuspid aortic valve stenosis: Insights from the BEAT registry 28
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 27
One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients presenting with acute myocardial infarction: Insight from the ULISSE registry 24
Latest STEMI treatment: a focus on current and upcoming devices 24
IntravaScular Lithotripsy for the Management of UndILatable Coronary StEnt: The SMILE Registry 24
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 23
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 23
New percutaneous interventions in heart failure 22
Methods to assess bioresorbable vascular scaffold devices behaviour after implantation 22
Multi-step percutaneous treatment of post-myocardial infarction ventricular septal defects: A case report and review of literature 21
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 21
Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation 20
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis 20
Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents: Insights of the TROFI II Trial 20
In-stent restenosis because of nickel hypersensitivity: A bioresorbable solution? 20
Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C6777T polymorphism 20
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 20
Procedural and clinical outcomes of type 0 versus type 1 bicuspid aortic valve stenosis undergoing trans-catheter valve replacement with new generation devices: Insight from the BEAT international collaborative registry 20
How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection? 19
Letter regarding "hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI" 19
Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre registro absorb italiano (RAI registry) 19
Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial) 19
Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy 19
Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis 18
Meta-Analysis Comparing Outcomes After Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents in Patients with Acute Coronary Syndromes 18
Outcomes of 10,312 patients treated with everolimus-eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium 14
Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term 14
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 13
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions 13
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 13
Sex-Related Differences in Long-Term Outcomes After Early-Onset Myocardial Infarction 13
Severely calcified coronary artery lesions: focus on interventional management 12
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 11
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 11
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 10
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 7
Time for implementing high-sensitivity cardiac troponin assays in emergency departments in Italy 6
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis 5
Alternative Approaches for Alcohol Septal Ablation in Hypertrophic Cardiomyopathy: The Call for a Personalized Treatment 5
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 5
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 5
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience 3
Pathophysiology, Functional Assessment and Prognostic Implications of Nutritional Disorders in Systemic Amyloidosis 3
Long-term outcomes of early-onset myocardial infarction with non-obstructive coronary artery disease (MINOCA) 2
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 2
Management of high and intermediate-high risk pulmonary embolism: A position paper of the Interventional Cardiology Working Group of the Italian Society of Cardiology 2
Totale 2.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 8 0 0 9 0 11 1 4 1 23 0
2020/2021227 5 0 3 37 76 0 37 2 2 7 48 10
2021/2022391 5 0 0 17 123 9 5 31 8 28 29 136
2022/2023793 94 59 13 50 110 36 3 35 364 1 12 16
2023/2024474 20 8 10 12 102 139 27 0 4 17 21 114
2024/202521 2 19 0 0 0 0 0 0 0 0 0 0
Totale 2.034